Suppr超能文献

治疗前雌二醇不能预测睾酮对枸橼酸氯米芬的反应。

Pre-treatment estradiol does not predict testosterone response to clomiphene citrate.

作者信息

Masterson John M, Cohen Jordan, Blachman-Braun Ruben, Machen Graham L, Sandlow Jay, Ramasamy Ranjith

机构信息

Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA.

出版信息

Transl Androl Urol. 2020 Apr;9(2):609-613. doi: 10.21037/tau.2020.01.30.

Abstract

BACKGROUND

Clomiphene citrate (CC) is a selective estrogen receptor modulator (SERM) used to stimulate ovulation in women. CC is used off-label in men to increase levels of endogenous testosterone (T) while potentially improving semen parameters by downregulating the inhibitory feedback of estradiol (E) on the male hypothalamus. Our objective was to determine whether pre-treatment E level is associated with greater total testosterone (TT) response to treatment with CC in men with low T.

METHODS

Following IRB approval (The University of Miami IRB No. 20170849), retrospective chart review was performed for all men prescribed CC (25 mg every other day) between January 1, 2015 and December 31, 2018. Age, body mass index (BMI), and prescription date were recorded for all patients. Pre- and post-treatment E, total T (TT), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels were recorded for all patients as well. Only men with pretreatment TT <300 ng/dL were included in the analysis in order to focus our study on men with low TT. Univariate linear regression analysis was performed to determinate the percent change in TT following CC treatment (dependent variable) and pre-treatment E and other variables including age, BMI, FSH, and LH (independent variables).

RESULTS

A total of 69 men with TT <300 ng/dL received CC 25 mg every other day. Mean age and BMI were 33.3±7.31 years and 35.4±5 kg/m respectively. Median pre-treatment E, TT, FSH, and LH were 18 [11.35-24.6] pg/mL, 226 [156-262] ng/dL, 5.1 [2.98-8.05] mIU/mL, and 4.5 [2.6-6.8] mIU/mL respectively. Post-treatment TT was 389 [263-592] ng/dL and TT% change was 102 [45.51-176.75]. Univariate linear regression showed that pre-treatment E (B=-0.595; R=0.001; P=0.757) did not significantly predict TT% change. TT% change could be significantly predicted by age in years (B=-7.428; R=0.057; P=0.048), pre-treatment FSH (B=-8.362; R=0.068; P=0.041), and pre-treatment LH (B=-20.67; R=0.096; P=0.027).

CONCLUSIONS

Pre-treatment E level does not appear to predict treatment response with CC in men with low T.

摘要

背景

枸橼酸氯米芬(CC)是一种选择性雌激素受体调节剂(SERM),用于刺激女性排卵。CC在男性中属于非适应证用药,可通过下调雌二醇(E)对男性下丘脑的抑制性反馈来提高内源性睾酮(T)水平,同时可能改善精液参数。我们的目的是确定在睾酮水平低的男性中,治疗前的E水平是否与CC治疗后总睾酮(TT)反应增强相关。

方法

在获得机构审查委员会批准(迈阿密大学机构审查委员会编号20170849)后,对2015年1月1日至2018年12月31日期间所有开具CC(隔日25mg)处方的男性进行回顾性病历审查。记录所有患者的年龄、体重指数(BMI)和处方日期。还记录了所有患者治疗前和治疗后的E、总T(TT)、促卵泡生成素(FSH)和促黄体生成素(LH)水平。为了将研究重点放在TT水平低的男性上,分析仅纳入治疗前TT<300ng/dL的男性。进行单变量线性回归分析,以确定CC治疗后TT的变化百分比(因变量)与治疗前E以及包括年龄、BMI、FSH和LH在内的其他变量(自变量)之间的关系。

结果

共有69名TT<300ng/dL的男性接受了隔日25mg的CC治疗。平均年龄和BMI分别为33.3±7.31岁和35.4±5kg/m²。治疗前E、TT、FSH和LH的中位数分别为18[11.35 - 24.6]pg/mL、226[156 - 262]ng/dL、5.1[2.98 - 8.05]mIU/mL和4.5[2.6 - 6.8]mIU/mL。治疗后TT为389[263 - 592]ng/dL,TT变化百分比为102[45.51 - 176.75]。单变量线性回归显示,治疗前E(B = -0.595;R = 0.001;P = 0.757)不能显著预测TT变化百分比。年龄(B = -7.4

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2a9/7215015/266fe63d3232/tau-09-02-609-f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验